Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31458619 | 1.00 | PIM1 (0.37) | PIM1MAPK1MAPK13MKNK1IRAK1 | |
| SCHEMBL31458578 | 0.77 | CDK2 (0.44) | PIM1MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL31458616 | 0.76 | MAPK1 (0.39) | PIM1MAPK1MAPK13TTK | |
| SCHEMBL31458604 | 0.75 | MAPK8 (0.36) | PIM1MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL31458626 | 0.74 | AHR (0.43) | PIM1MAPK1MKNK1MAPK8MAPK9 | |
| SCHEMBL31458606 | 0.73 | PIM1 (0.33) | PIM1MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL31458746 | 0.70 | PDE1B (0.36) | PIM1MAPK1MAPK8MAPK9MAPK10 | |
| SCHEMBL31458748 | 0.69 | MAPK1 (0.35) | PIM1MAPK1MKNK1MAPK8MAPK9 | |
| SCHEMBL31458682 | 0.67 | IRAK4 (0.35) | MAPK1 | |
| SCHEMBL26979104 | 0.67 | MKNK1 (0.39) | PIM1MAPK1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096061-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |